<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1052243361488264&amp;ev=PageView&amp;noscript=1">

A Video From FlowMetric's CEO & Founder


FlowMetric Fast Facts

  • GLP and GCP-compliant, CLIA-certified, High Complexity Laboratory
  • Global Presence in North America, Europe, and soon Asia-Pac (late 2020)
  • Expertise in Cellular and Gene Therapy, Immunology, Oncology, and Infectious Diseases
  • Respected Global Leader in Flow Cytometry with an Ability for up to 40 Parameter Analysis
  • Quality-driven Services that Accelerate Clinical Trials, Pre-Clinical, Toxicity, and Discovery Initiatives
  • Over a Decade of Partnering with Top Pharma and Biotech Companies with >90% Repeat Business   

Why Choose FlowMetric

FlowMetric was established to deliver decision-enabling data on programs that matter the most to you. Partners choose us because of our expertise, our focus, our approach and results we have delivered.

Learn More

Tissue Dissociation Steps Video


Get Our Latest Whitepaper

New call-to-action

FlowMetric in the News

  • PharmExec.com - Ren Capocasale, CEO of Flowmetric, featured in an article on PharmaExec.com and talks about the PABC. View Post Summary
  • Press Release - FlowMetric Life Sciences, Inc. Receives CLIA High Complexity Laboratory Certification View Post Summary
  • Press Release - FlowMetric Diagnostics, Inc. Announces the Expansion of Their Core Services to Include Serological Antibody Testing for SARS-CoV-2 Exposure View Post Summary
  • The Intelligencer - Doylestown Biotechnology center, Blumberg Institute, on the front lines of coronavirus fight View Post Summary
  • Press Release - Capital Health Launches COVID-19 Antibody Testing Initiative View Post Summary

News from FlowMetric

  • GLP concepts in Flow Cytometry View Post Summary

    What is Good Laboratory Practice (GLP)?

    No doubt you have come across the term GLP (Good Laboratory Practice) when considering conducting a nonclinical study. But when should a study be performed under GLP conditions? 

    Read the full article »
  • Sample Preparation for Flow Cytometry - Best Practices View Post Summary

    The idiom, garbage in, garbage out applies to many areas of scientific research, including flow cytometry. Good sample preparation is critical to accurate and sensitive cytometry analysis of cells, wherever their origin. 

    Read the full article »
  • COVID-19 Serological-Based Testing: The Impact on Global Public Health View Post Summary

    Following the outbreak of SARS-CoV-2 at the end of 2019, the FDA’s policy path has been an evolving balance of risk and benefit assessments, all made in real-time during the unfolding pandemic. When it came to testing, the FDA allowed higher levels of flexibility in performance and processes when it came to serological testing compared with that of the molecular diagnostic testing. This was largely because the serological detection of antibodies is not intended to diagnose active SARS-CoV-2 infection but rather help answer critical questions over the prevalence of the infection within different populations, its rate of spread, and immunity to the disease following infection.

    Read the full article »
  • CLIA & GCLP standards for clinical trial support View Post Summary

    Providing laboratory support testing for a clinical trial by meeting trial sponsors’ growing needs, all while meeting stringent regulatory requirements? It’s possible.

    Read the full article »
  • Role of Cytokine Release Syndrome (CRS) in Severe COVID-19 and Cellular Therapy View Post Summary

    What is Cytokine Release Syndrome (CRS)?

    Cytokine-associated toxicity, also known as cytokine release syndrome (CRS), is a non–antigen-specific toxicity that occurs as a result of high-level immune activation and can be triggered by a variety of factors such as certain drugs and infections.  As the name implies, several cytokines are released and elevated during CRS. The main cytokines implicated during the pathogenesis of CRS include interleukin-6 (IL-6), tumor necrosis factor (TNF-α),  interferon-γ (IFN-γ) and interleukin-10 (IL-10) (Fig.1). 

    Read the full article »